Climb Bio, Inc.
Clinical trials sponsored by Climb Bio, Inc., explained in plain language.
-
New drug shows promise for rare kidney disease
Disease control Recruiting nowThis study tests a new drug, budoprutug, in 45 adults with primary membranous nephropathy, a kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can help reduce protein in the urine, a sign of kidney damage. Participants will rec…
Phase: PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New drug budoprutug aims to boost platelets in ITP patients
Disease control Recruiting nowThis study tests a new drug, budoprutug, in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The main goal is to check safety and find the right dose, while also seeing if it helps raise platelet counts.…
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New lupus drug candidate enters early human testing
Disease control Recruiting nowThis early-stage study is testing a new drug called budoprutug in 30 adults with active lupus who haven't responded well to other treatments. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might help…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug CLYM116 begins first human safety tests
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, CLYM116, in 48 healthy adults aged 18 to 60. The main goal is to see if the drug is safe and how the body processes it after one or several injections under the skin. Participants will be randomly assigned to receive either the drug o…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC